BeOne Medicines Ltd.
ONC · XNASCIK 1651308fmd_0BNEXY07365K1J9D08AF2VK9X7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 238 | 198 | 428 | 309 | 1,176 | 1,416 | 2,459 | 3,810 | 5,343 |
| Net interest income | 0 | (4) | 14 | 9 | 2 | (16) | 52 | 74 | – | – |
| Cost of revenue | 0 | 5 | 29 | 71 | 71 | 165 | 286 | – | – | – |
| Gross profit | 1 | 233 | 170 | 357 | 238 | 1,011 | 1,129 | 2,079 | 3,216 | 4,674 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | (9) | (17) | (1) |
| Research and development | 98 | 269 | 679 | 927 | 1,295 | 1,459 | 1,641 | 1,779 | 1,953 | 2,146 |
| Selling, general and administrative | 20 | 63 | 195 | 388 | 600 | 990 | 1,279 | 1,508 | 1,831 | 2,081 |
| Operating income | (117) | (98) | (706) | (960) | (1,658) | (1,439) | (1,790) | (1,208) | (568) | 447 |
| Interest expense | – | – | 13 | 15 | 18 | 29 | 22 | 4 | 22 | 58 |
| Interest and investment income | – | – | – | – | – | – | – | 78 | 70 | 71 |
| Other non-operating income (expense) | (1) | 12 | 2 | 7 | 37 | 16 | (224) | 308 | (13) | (43) |
| Income before taxes | (119) | (91) | (690) | (944) | (1,618) | (1,439) | (1,961) | (826) | (533) | 417 |
| Income tax expense | 0 | 2 | (16) | 7 | 10 | 19 | 43 | 56 | 112 | 130 |
| Net income from continuing operations | (119) | (93) | (674) | (951) | (1,629) | (1,458) | (2,004) | (882) | (645) | 287 |
| Net income | (119) | (93) | (674) | (949) | (1,625) | (1,458) | (2,004) | (882) | (645) | 287 |
| Net income to common shareholders | (119) | (93) | – | – | – | – | – | – | – | – |